Pfizer (PFE) Updates FY13 Earnings Guidance
Pfizer (PFE) updated its FY13 earnings guidance on Tuesday. The company provided earnings per share guidance of $2.20-2.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.29. The company issued revenue guidance of $56.2-58.2 billion, compared to the consensus revenue estimate of $57.72 billion.
A number of research firms have also recently commented on PFE. Analysts at BMO Capital Markets raised their price target on shares of Pfizer to $30.00 in a research note to investors on Monday. They now have an outperform rating on the stock. On a related note, analysts at Barclays Capital raised their price target on shares of Pfizer from $24.00 to $25.00 in a research note to investors on Tuesday, January 22nd. They now have an equal weight rating on the stock. Finally, analysts at JPMorgan Chase reiterated an overweight rating on shares of Pfizer in a research note to investors on Tuesday, January 22nd. They now have a $29.00 price target on the stock.
Sixteen research analysts have rated the stock with a buy rating, three have given an overweight rating, and five have given a hold rating to the company’s stock. Pfizer presently has a consensus rating of overweight and a consensus price target of $28.63.
Shares of Pfizer (PFE) opened at 26.84 on Tuesday. Pfizer (PFE) has a 52 week low of $20.75 and a 52 week high of $27.30. The stock’s 50-day moving average is currently $25.94. The company has a market cap of $197.6 billion and a P/E ratio of 21.02.
Pfizer last announced its earnings results on Tuesday, January 29th. The company reported $0.47 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.44 by $0.03. The company had revenue of $15.10 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the company posted $0.50 earnings per share. The company’s quarterly revenue was down 6.6% on a year-over-year basis. Pfizer has set its FY13 guidance at $2.20-2.30 EPS. Analysts expect that Pfizer (PFE) will post $2.16 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Tuesday, March 5th. Stockholders of record on Friday, February 1st will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 3.56%. The ex-dividend date is Wednesday, January 30th. This is a boost from Pfizer’s previous quarterly dividend of $0.22.
Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company applies science and its global resources to improve health and well-being at every stage of life.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.